Author

Hyunju Song

Institution: Dankook University

Observed institution: Dankook University

ORCID: 0009-0001-2204-4835

Observed ORCID: 0009-0001-2204-4835

OpenAlex ID: A5132898090

Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non–Small Cell Lung Cancer

2026 · Yo Han Jeon, Ahjin Lim, et al. · Cancer Research Communications · 1

Figure 3 from Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non–Small Cell Lung Cancer

2026 · Yo Han Jeon, Ahjin Lim, et al.

Table S1 from Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non–Small Cell Lung Cancer

2026 · Yo Han Jeon, Ahjin Lim, et al.

Figure S2 from Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non–Small Cell Lung Cancer

2026 · Yo Han Jeon, Ahjin Lim, et al.

Data from Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non–Small Cell Lung Cancer

2026 · Yo Han Jeon, Ahjin Lim, et al.

Figure S3 from Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non–Small Cell Lung Cancer

2026 · Yo Han Jeon, Ahjin Lim, et al.

Figure S1 from Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non–Small Cell Lung Cancer

2026 · Yo Han Jeon, Ahjin Lim, et al.

Figure 2 from Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non–Small Cell Lung Cancer

2026 · Yo Han Jeon, Ahjin Lim, et al.

Figure 1 from Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non–Small Cell Lung Cancer

2026 · Yo Han Jeon, Ahjin Lim, et al.

Table 1 from Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non–Small Cell Lung Cancer

2026 · Yo Han Jeon, Ahjin Lim, et al.

Abstract 7736: Rare EGFR cis compound L833V/H835L mutation in non-small cell lung cancer is oncogenic and a therapeutic target of EGFR tyrosine kinase inhibitors

2026 · Yo Han Jeon, Ahjin Lim, et al. · Cancer Research

Works count: 11

Citation count: 1

H-index: 1

I10-index: